Photo: Covetrus · CC0 · Wikimedia Commons

Headquarters: United States — Industry / veterinary distribution

Covetrus

Also known as: Covetrus, Inc.

Updated on 14 November 2026

US distributor of veterinary medicines and supplies.

Covetrus is a US distributor of veterinary medicines and supplies, controlled since 2022 by the investment firms Clayton, Dubilier & Rice and TPG. Its subsidiary Covetrus North America was convicted in 2024 over the illegal distribution of prescription veterinary drugs. The 2022 take-private was challenged by shareholders, who obtained a $70 million settlement in 2026. In November 2026 the FTC and several states sued to block its merger with MWI Veterinary Supply.

Are you concerned? Right of reply

3Documented controversies

6Sources

0Formal charges · all time

0Convictions

§ Legal statuses reflect the documented sources as of the date shown; they replace neither court decisions nor the presumption of innocence. Counts are not a rating. Methodology

I. Documented controversies

2022–April 2026

2022-2026: Clayton, Dubilier & Rice take-private challenged by shareholders, $70 million settlement

Civil / administrative proceedings — against Clayton, Dubilier & Rice and former Covetrus directors

Protagonist not prosecuted — these proceedings are not counted in their formal charges or convictions.

Minority shareholders accused Clayton, Dubilier & Rice, the controlling shareholder, and other defendants of distorting the 2022 take-private process of Covetrus and of misinforming shareholders. The Delaware Court of Chancery approved a $70 million settlement in April 2026, without a ruling on the merits.

State of the evidence: Settlement notice and plaintiffs’ counsel’s account of the approval.
Legal status — source text: $70m civil settlement approved by Delaware Chancery Court.
Attribution: Allegedly improper conduct during the Covetrus take-private process.
Person targeted by the proceedings: Clayton, Dubilier & Rice and former Covetrus directors
Role of the person profiled: Protagonist not prosecuted

Sources · 2

[1]
Kessler Topaz Meltzer & CheckKTMC Secures $70 Million Settlement in Stockholder Litigation Challenging Covetrus-Clayton, Dubilier & Rice Take-Private Deal12 May 2026MediaHigh reliability
[2]
Labaton Keller SucharowBucks County Employees’ Retirement System v. Clayton Dubilier & Rice LLC (Covetrus Litigation)MediaHigh reliability

Last verified: 14 November 2026

Add to this entry Any news?

November 13, 2026

2026: FTC lawsuit to block the merger with MWI Veterinary Supply

Civil / administrative proceedings

On 13 November 2026 the FTC and several state attorneys general went to federal court to stop Covetrus and its owners (Clayton, Dubilier & Rice and TPG) from acquiring MWI Veterinary Supply, a Cencora subsidiary and its largest competitor. According to the authorities, the merger would reduce competition in veterinary product distribution and raise costs for veterinarians. No ruling on the merits has been made.

State of the evidence: FTC complaint and case docket; predicted price effects remain allegations.
Legal status — source text: Antitrust lawsuit pending in the Southern District of New York.
Attribution: Involvement in a challenged acquisition, as acquéreur de MWI.

Sources · 1

[1]
Nebraska Attorney GeneralNebraska, FTC, and Partnering States Sue Covetrus Inc. and MWI Veterinary Supply, Inc. to Prevent Anticompetitive Acquisition13 November 2026Official documentHigh reliability

Last verified: 14 November 2026

Add to this entry Any news?

2019–May 2024

2024: subsidiary Covetrus North America convicted over illegal distribution of veterinary drugs

Criminal conviction — against Covetrus North America LLC (subsidiary)

Protagonist not prosecuted — these proceedings are not counted in their formal charges or convictions.

Covetrus North America LLC, a separate entity, pleaded guilty in February 2024 and was sentenced in May over unlawful distribution of veterinary prescription drugs. Its sanctions included more than $23 million in fines and forfeiture and one year of probation.

State of the evidence: DOJ and FDA releases identify the subsidiary as the defendant.
Legal status — source text: Criminal conviction of a subsidiary, not Covetrus Inc.
Attribution: Wrongdoing attributed to a legally distinct subsidiary.
Person targeted by the proceedings: Covetrus North America LLC (subsidiary)
Role of the person profiled: Protagonist not prosecuted

Sources · 3

[1]
U.S. Attorney’s Office, Western District of VirginiaCovetrus Pleads Guilty to Criminal Misbranding of Veterinary Prescription Drugs12 February 2024Official documentHigh reliability
[2]
U.S. Food and Drug AdministrationCovetrus Sentenced for Criminal Misbranding of Prescription Drugs9 May 2024Official documentHigh reliability
[3]
U.S. Attorney’s Office, Western District of VirginiaCovetrus Sentenced for Criminal Misbranding of Prescription Drugs9 May 2024Official documentHigh reliability

Last verified: 14 November 2026

Add to this entry Any news?

II. Constellation of documented links

No documented link with another published profile for now.

Two profiles are linked when a documented controversy of one names the other. The link points to that controversy and its sources; it does not indicate a personal relationship.

III. Has something changed?

A new court decision, a missing source, a mistake? Tell us what should be updated: every request is read by the editorial team.

Support the archive

Controversia checks and updates its profiles independently. Support is optional and has no effect on the content of profiles.

Donate

Controversia profile, updated 14 November 2026. Latest version: https://controversia.info/en/fiche/covetrus